e-learning
resources
London 2016
Sunday, 04.09.2016
Pulmonary drug delivery
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of antistatic AeroChamber Plus® Flow-Vu® spacer on the systemic bioavailability of CHF5993 a novel triple pMDI
Fabrizia Mariotti (Parma, Italy), Fabrizia Mariotti, Sara Collarini, Stefano Vezzoli, Daniela Acerbi, Mario Scuri, Piotr Kuna
Source:
International Congress 2016 – Pulmonary drug delivery
Session:
Pulmonary drug delivery
Session type:
Thematic Poster
Number:
964
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Fabrizia Mariotti (Parma, Italy), Fabrizia Mariotti, Sara Collarini, Stefano Vezzoli, Daniela Acerbi, Mario Scuri, Piotr Kuna. Effect of antistatic AeroChamber Plus® Flow-Vu® spacer on the systemic bioavailability of CHF5993 a novel triple pMDI. Eur Respir J 2016; 48: Suppl. 60, 964
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
In vitro validation of the use of a spacer with an extrafine beclomethasone/formoterol formulation
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
The effect of inhalation duration on lung deposition with a pressurized metered-dose inhaler (pMDI)
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Systemic exposure and lung bioavailability across two different dose strengths of CHF5993 a novel Triple pMDI
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Cardiovascular safety of extrafine beclomethasone/formoterol (BDP/FF) delivered via a novel dry powder inhaler (NEXThaler®) in COPD patients
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Effect of interval between actuations of albuterol HFA inhalers on their aerosol characteristics
Source: International Congress 2016 – Paediatric asthma: recurrent, persistent, or severe obstruction and lung function techniques
Year: 2016
In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Pharmacokinetics, safety and tolerability of CHF5993 a triple pMDI in renal impaired patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Valved holding chambers (VHCs) can have different medication delivery performance as a function of delay interval following actuation of the pressurized metered dose inhaler (pMDI)
Source: International Congress 2014 – Respiratory symptoms in primary care populations
Year: 2014
Eliminating in-vitro drug-drug interactions in dual and triple fixed-dose combination therapies using a novel cosuspension metered dose inhaler platform
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Biopharmaceutical and chemical compatibility of the combination of salbutamol hemisuccinate and methatropium iodide
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015
Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Assessment of the bioequivalence of two DPIs containing fluticasone and salmeterol, in patients with controlled or partly controlled asthma
Source: International Congress 2016 – Clinical characteristics of asthma
Year: 2016
Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Asthma management: important issues
Source: Eur Respir Rev 2005; 14: 147-151
Year: 2005
The add-on effect of tiotropium bromide to ICS/LABA combination inhaler for the patients with severe uncontrolled asthma
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Ease of use of a two-strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015
Equivalence of an innovative multidose salmeterol/fluticasone dry powder inhaler vs comparator in paediatric asthma
Source: Annual Congress 2013 –Asthma treatment and management in children
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept